Brind.

I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks.

1 report, 0 independent Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

I-Mab presented clinical data for Givastomig, combining it with nivolumab and mFOLFOX6, while Trump-era tariffs benefited AI stocks.

Who's involved

What this event is mainly about
Donald Trump

How it developed

Newest first. Tap a step to see who reported it.
  1. AI stocks are benefiting from Trump tariffs and onshoring, alongside potential merger talks involving Northern Trust and Bank of New York Mellon.Sub-event
  2. I-Mab presented Givastomig data while Trump tariffs benefited AI stocks.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet